CRISPR ‐Cas9 screen reveals that inhibition of enhancer of zeste homolog 2 sensitizes malignant T cells to dimethyl‐fumarate‐induced cell death
The FEBS Journal · 2026
DOI: 10.1111/febs.70208 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2026. Verfasst von Jan P Teubner und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg…. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, CRISPR-Cas Systems, Dimethyl Fumarate, Lymphoma, T-Cell, Cutaneous. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wilhelm Sander-Stiftung.
Abstract (Originalsprache)
Constitutive activation of the nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) pathway is a hallmark of many lymphocyte‐associated cancers, including cutaneous T‐cell lymphoma (CTCL) and its leukemic variant, the Sézary syndrome. Dimethyl fumarate (DMF) has been identified as a promising NF‐κB‐targeted therapy and has shown positive outcomes in a phase II clinical trial involving patients with Sézary syndrome. However, limited responsiveness remains a significant challenge. Through a genome‐wide clustered regularly interspaced short palindromic repeats (CRISPR)‐Cas9 screen, we identified enhancer of zeste homolog 2 (EZH2; also known as histone‐lysine N‐methyltransferase) as a critical target for enhancing DMF‐induced cell death. EZH2, the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), is responsible for the methylation of histone H3 (H3K27). Combining DMF with the US Food and Drug Administration (FDA)‐approved EZH2 inhibitor tazemetostat significantly increases cell death in patient‐derived CTCL cells, offering a promising strategy to improve therapeutic outcomes and overcome limited responsiveness to DMF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, Germany.
- Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim/University of Heidelberg, Mannheim, Germany.
- Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Germany.
ORCID-Profile: Deniz Tümen, Karsten Gülow
Förderung
- Wilhelm Sander-Stiftung
Zitieren
APA
Teubner, J. P., Tümen, D., Kandulski, A., Heumann, P., Mester, P., Aschenbrenner, E., Pollinger, K., Gunckel, M., Volz, B., Hein, T., Beltzig, P. L., Tengler, L., Voll, F., Kreutz, M., Kunst, C., Nicolay, J. P., Müller, M., & Gülow, K. (2026). CRISPR ‐Cas9 screen reveals that inhibition of enhancer of zeste homolog 2 sensitizes malignant T cells to dimethyl‐fumarate‐induced cell death. The FEBS Journal. https://doi.org/10.1111/febs.70208
Vancouver
Teubner JP, Tümen D, Kandulski A, Heumann P, Mester P, Aschenbrenner E, et al. CRISPR ‐Cas9 screen reveals that inhibition of enhancer of zeste homolog 2 sensitizes malignant T cells to dimethyl‐fumarate‐induced cell death. The FEBS Journal. 2026. doi:10.1111/febs.70208
BibTeX
@article{Teubner2026,
author = {Teubner, Jan P and Tümen, Deniz and Kandulski, Arne and Heumann, Philipp and Mester, Patricia and Aschenbrenner, Elisabeth and Pollinger, Kirstin and Gunckel, Manuela and Volz, Barbara and Hein, Tobias and Beltzig, Paul L and Tengler, Luisa and Voll, Florian and Kreutz, Marina and Kunst, Claudia and Nicolay, Jan P and Müller, Martina and Gülow, Karsten},
title = {CRISPR ‐Cas9 screen reveals that inhibition of enhancer of zeste homolog 2 sensitizes malignant T cells to dimethyl‐fumarate‐induced cell death},
journal = {The FEBS Journal},
year = {2026},
doi = {10.1111/febs.70208}
}
EUVIMED